Skip to content

Predicine to Present 15 Liquid Biopsy Studies at AACR 2024

HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) — Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15?ctDNA?studies?at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies.

Predicine to Present 15 Liquid Biopsy Studies at AACR 2024
author avatar
LabNews Media LLC
The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu
LabNews Media LLC

LabNews Media LLC

The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They have been bestselling authors, science writers, and science journalists since 1994.More details about their writing at X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu